Chief Physician and Doctoral Supervisor. He currently serves as Director of the Department of General Internal Medicine and Director of the Department of Lymphoma Medicine at Peking University Cancer Hospital. He previously held the positions of Assistant to the President, Deputy Party Secretary, Vice‑President and Party Secretary of Peking University Cancer Hospital.

Specialty: Diagnosis, treatment and translational research of lymphoma. He graduated from the Department of Clinical Medicine, Third Military Medical University. He was a visiting scholar at the Bone Marrow Transplantation Center of Hadassah Medical Center, Hebrew University of Jerusalem, Israel. He is a renowned expert in lymphoma diagnosis and treatment. He pioneered specialized lymphoma diagnosis and treatment nationwide and built a model lymphoma diagnosis‑treatment center as well as an autologous hematopoietic stem cell transplantation center, with more than 100,000 patients treated in total. He led the formulation of the Chinese Society of Clinical Oncology (CSCO) Lymphoma Diagnosis and Treatment Guidelines, established a national multi‑center research collaboration network, promoted standardized diagnosis and treatment across China, and engaged grassroots hospitals in more than 30 provinces and municipalities in standardized lymphoma clinical practice. He has led or participated in over 300 domestic and international registered clinical trials, accounting for more than 75 % of China’s new‑drug research and development for lymphoma, among which over 80 % are projects under his leadership. As of 2024, his work has facilitated the domestic approval of 31 new anti‑lymphoma drugs or new indications. Five sets of clinical trial data have been incorporated into the US NCCN Guidelines. He keeps advancing the launch of innovative drugs and the optimization of treatment strategies to improve patient survival outcomes. He presided over major special projects of the Ministry of Science and Technology as well as sub‑projects of the 863 Program and 973 Program. As corresponding author, he has published more than 200 papers in journals including Nature Medicine, Journal of Hematology & Oncology and Blood.

Awards: The 13th WuXi AppTec Life Science Research Award; the Second‑Class Prize of the 2023 Chinese Medical Science and Technology Progress Award as the first completer; honored as one of the 13th Batch of “Beijing Distinguished Scientists, Technologists and Managers”. He was a delegate to the 11th, 12th, 13th and 14th Congresses of Party Members of Peking University, and received Li Dazhao Award, Peking University’s highest honor for outstanding Party workers.